Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database

References

• Gibbons C, Blundell J, Tetens Hoff S, et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obesity Metab. 2021;23(2):581–588.
   PubMed Web of Science ®Google Scholar
• Rodbard HW. The clinical impact of GLP-1 receptor agonists in type 2 diabetes: focus on the long-acting analogs. Diabetes Technol Ther. 2018;20(S2):33–41.
   Google Scholar
• Deacon CF, Mannucci E, Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obesity Metab. 2012;14(8):762–767.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090.
   PubMed Web of Science ®Google Scholar
• Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–1124.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102.
   PubMed Web of Science ®Google Scholar
• Boye K, Ross M, Mody R, et al. Patients‘ preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study. Diabetes Obesity Metab. 2021;23(2):508–519.
   PubMed Web of Science ®Google Scholar
• Andersen A, Knop FK, Vilsbøll T. A pharmacological and clinical overview of oral Semaglutide for the treatment of type 2 diabetes. Drugs. 2021;81(9):1003–1030.
   PubMed Web of Science ®Google Scholar
• Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021;12:645563.
   PubMed Web of Science ®Google Scholar
• Korsatko S, Jensen L, Brunner M, et al. Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obesity Metab. 2018;20(11):2565–2573.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of Hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, et al. 9 pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl1):S125–43.
   PubMedGoogle Scholar
• Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020;26(1):107–139.
   PubMed Web of Science ®Google Scholar
• Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends in Cardiovascular Medicine 2021;S1050173821001584.
   Google Scholar
• Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity 2020;28(6):1050–1061.
   Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly Semaglutide in adults with overweight or obesity. New Engl. J. Med 2021;384(11):989–1002.
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly Semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286.
   PubMed Web of Science ®Google Scholar
• Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–367.
   PubMed Web of Science ®Google Scholar
• Lingvay I, Hansen T, Macura S, et al. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Res Care. 2020;8(2):e001706.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889–897.
   PubMed Web of Science ®Google Scholar
• Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563–574.
   PubMed Web of Science ®Google Scholar
• Frau S, Font Pous M, Luppino MR, et al. Risk Management Plans: are they a tool for improving drug safety? Eur J Clin Pharmacol. 2010;66(8):785–790.
   PubMed Web of Science ®Google Scholar
• Blake KV, Prilla S, Accadebled S, et al. European medicines agency review of post-authorisation studies with implications for the European network of centres for pharmacoepidemiology and pharmacovigilance: POST-AUTHORISATION STUDIES. Pharmacoepidemiol Drug Saf. 2011;20(10):1021–1029.
   PubMed Web of Science ®Google Scholar
• Santoro A, Genov G, Spooner A, et al. Promoting and protecting public health: how the European Union Pharmacovigilance system works. Drug Saf. 2017;40(10):855–869.
   PubMed Web of Science ®Google Scholar
• Di Mauro G, Zinzi A, Scavone C, et al. PCSK9 inhibitors and neurocognitive adverse drug reactions: analysis of individual case safety reports from the eudravigilance database. Drug Saf. 2021;44(3):356–367.
   Web of Science ®Google Scholar
• Rafaniello C, Ferrajolo C, Sullo MG, et al. Cardiac events potentially associated to remdesivir: an analysis from the European spontaneous adverse event reporting system. Pharmaceuticals. 2021;14(7):611.
   Web of Science ®Google Scholar
• Inzucchi SE, Davies MJ, Khunti K, et al. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. Diabetes Obesity Metab. 2021;23(2):425–433.
   PubMed Web of Science ®Google Scholar
• Bain SC, Hansen BB, Malkin SJP, et al. Oral Semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Ther. 2020;11(1):259–277.
   PubMed Web of Science ®Google Scholar
• Zhan M, Xu T, Wu F, et al. Sitagliptin in the treatment of type 2 diabetes: a meta-analysis: sitagliptin for type 2 diabetes. J Evid Med. 2012;5(3):154–165.
   Google Scholar
• Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(3):521–539.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–2301.
   PubMed Web of Science ®Google Scholar
• Kane MP, Triplitt CL, Solis-Herrera CD. Management of type 2 diabetes with oral semaglutide: practical guidance for pharmacists. Am J Health Syst Pharm. 2021;78(7):556–567.
   PubMed Web of Science ®Google Scholar
• Meier JJ. Efficacy of Semaglutide in a subcutaneous and an oral formulation. Front Endocrinol. 2021;12:645617.
   PubMed Web of Science ®Google Scholar
• Seidu S, Mellbin L, Kaiser M, et al. Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? Prim Care Diabetes. 2021;15(1):59–68.
   PubMed Web of Science ®Google Scholar
• Goldenberg RM, Steen O. Semaglutide: review and place in therapy for adults with type 2 diabetes. Can J Diabetes. 2019;43(2):136–145.
   PubMed Web of Science ®Google Scholar
• Latini R, Staszewsky L. Semaglutide and effective weight control. The Lancet. 2021;397(10278):942–943.
   PubMed Web of Science ®Google Scholar
• Lopes A, Roque F, Morgado S, et al. Behavioral sciences in the optimization of pharmacological and non-pharmacological therapy for type 2 diabetes. Behav Sci. 2021;11(11):153.
   PubMedGoogle Scholar
• Nauck MA, Quast DR. Cardiovascular safety and benefits of Semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol. 2021;12:645566.
   PubMed Web of Science ®Google Scholar
• Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61–69.
   PubMed Web of Science ®Google Scholar
• Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol. 2001;2(6):349–351.
   PubMedGoogle Scholar
• Khan MAB, Hashim MJ, King JK, et al. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health. 2019;10(1):107.
   Web of Science ®Google Scholar
• Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obesity Metab. 2022;24(1):94–105.
   PubMed Web of Science ®Google Scholar
• Jendle J, Birkenfeld A, Silver R, et al. Effect of gastrointestinal adverse events on treatment satisfaction in Semaglutide treatment of type 2 diabetes. Value Health. 2017;20(9):A484.
   Web of Science ®Google Scholar
• Novo Nordisk A/S. Ozempic - SUMMARY OF PRODUCT CHARACTERISTICS. 2018.
   Google Scholar
• Novo Nordisk A/S. Rybelsus - SUMMARY OF PRODUCT CHARACTERISTICS. 2020.
   Google Scholar
• Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral Semaglutide compared with placebo and subcutaneous Semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460.
   PubMed Web of Science ®Google Scholar
• Williams DM, Ruslan AM, Khan R, et al. Real-world clinical experience of Semaglutide in secondary care diabetes: a retrospective observational study. Diabetes Ther. 2021;12(3):801–811.
   PubMed Web of Science ®Google Scholar
• Jain AB, Kanters S, Khurana R, et al. Real-world effectiveness analysis of switching from liraglutide or dulaglutide to Semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE-DM study. Diabetes Ther. 2021;12(2):527–536.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral Semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–2281.
   PubMed Web of Science ®Google Scholar
• Eliasson B, Ericsson Å, Fridhammar A, et al. Long-term cost effectiveness of oral Semaglutide versus empagliflozin and sitagliptin for the treatment of type 2 diabetes in the Swedish setting. PharmacoEcon Open. 2022;6(3):343–354.
   PubMed Web of Science ®Google Scholar
• Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14–19.
   PubMed Web of Science ®Google Scholar
• Buse JB, Bode BW, Mertens A, et al. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. BMJ Open Diabetes Res Care. 2020;8(2):e001649.
   PubMed Web of Science ®Google Scholar
• Lajthia E, Bucheit JD, Nadpara PA, et al. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series. Pharm Pract. 2019;17(4):1588.
   PubMed Web of Science ®Google Scholar
• Jung HN, Cho YK, Min SH, et al. Free versus fixed-ratio combination of basal insulin and GLP-1 receptor agonists in type 2 diabetes uncontrolled with glp-1 receptor agonists: a systematic review and indirect treatment comparison. Front Endocrinol. 2022;13:870722.
   PubMed Web of Science ®Google Scholar
• Anderson JE. Combining glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes. Diabetes Spectr. 2020;33(2):165–174.
   PubMedGoogle Scholar
• Zhao Z, Tang Y, Hu Y, et al. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data. Ann Transl Med. 2021;9(18):1482.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen M, Liu L, et al. Difference in gastrointestinal risk associated with use of GLP-1 receptor agonists: a real-world pharmacovigilance study. Diabetes Metab Syndr Obes Targets Ther. 2022;Volume;15(1):155–163.
   PubMedGoogle Scholar